The somewhat weak Q3 situation continues in Q4 2024.
Redeye gives a short comment on today’s news that Curasight’s TO2 program yielded DKK5.
Aspo downgraded its full year EBITA guidance to EUR ~30m (previously over EUR 32m).
After market close on 9 December, Husqvarna issued a profit warning due to challenging market condit...
Gapwaves has received an order from a new North American Tier-1 for Gapwaves MLW waveguide antenna i...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) meddelade den 6 december 2024 att bolaget har...
- Strong momentum and long runway for growth highlighted - Military modernisation and market share g...
Redeye is encouraged by Climeon's sale of one HP300 unit to NovaAlgoma Cement Carriers that was anno...
Systemair redovisade en rapport för verksamhetsårets andra kvartal som fick ett mycket positivt mott...
Redeye provides its Q3 2024 update for the Swedish Quality Microcap theme.
Uniquely positioned in an attractive market Positioned for further growth and scaling Key customer r...
Genom marknadsföringssatsningar, registrerat JV i Kina, ett breddat distributionsnätverk samt godkän...
CEO highlighted churn of 1.8% International content providers are key for growth Potential M&A oppor...
PHI är ett medicintekniskt bolag som utvecklar och marknadsför icke-invasiva time-lapse imaging-inst...
Ework is not just a consultancy broker Demand will gradually pick up, but the pace is uncertain Marg...
Signs of market improving from low levels Good activity with Aira, but new partnerships will take ti...
Prostatype Genomics förväntar sig svar inom kort från den amerikanska administrationen av Medicare o...
Redeye is encouraged by the announcement of a strategic restructuring of Champion Health Plus.
CirChem (”CirChem” eller ”Bolaget”) uppvisade en rekordstark nettoomsättning om 10,2 MSEK (0,7) unde...
AcuCort AB (”AcuCort” eller ”Bolaget”) har under Q3-24 tagit viktiga steg i kommersialiseringsresan,...